“两票制”下药品流通企业的发展方向探讨
|
摘要
目的:为"两票制"下药品流通企业的发展提供建议。方法:通过分析"多票制"对药品流通企业的消极影响和"两票制"对药品流通企业的积极影响,探讨"两票制"下药品流通企业的发展方向。结果与结论:"多票制"使得药品价格居高不下,造成药品流通成本高、药品质量难把关。"两票制"则规范了药品流通领域的秩序,节约了医疗药品资源,降低了药品价格,稳固了资金链条。"两票制"下药品流通企业应积极适应医药市场转型、重构药品流通链条,相关部门及各主体之间应建立医药流通网络一体化,药品流通主体要促进票、账、货核对工作,规范回账日期,稳步实施改革。
OBJECTIVE:To provide suggestions for the development of drug circulation enterprises under "two invoice system". METHODS:By analyzing the negative effects of"multi invoice system"on drug circulation enterprises and positive effects of"two invoice system"on drug circulation enterprises,the development direction of drug circulation enterprises was investigated under"two invoice system". RESULTS & CONCLUSIONS:The"multi invoice system"formulates the high drug price,causes high drug circulation cost and is difficult to check drug quality. The"two invoice system"standardizes the order of drug circulation field,saves medical drug source,reduce drug price and kept capital chain stable. Under"two invoice system",drug circulation enterprises should actively adapt to the transformation of medical and pharmaceutical market,and reconstruct the chain of drug circulation. The integration of medical circulation network should be established between the relevant departments and various subjects. Drug circulation subjects should promote the check of ticket,account and goods,standardize the date of back account,implement reform stably.
OBJECTIVE:To provide suggestions for the development of drug circulation enterprises under "two invoice system". METHODS:By analyzing the negative effects of"multi invoice system"on drug circulation enterprises and positive effects of"two invoice system"on drug circulation enterprises,the development direction of drug circulation enterprises was investigated under"two invoice system". RESULTS & CONCLUSIONS:The"multi invoice system"formulates the high drug price,causes high drug circulation cost and is difficult to check drug quality. The"two invoice system"standardizes the order of drug circulation field,saves medical drug source,reduce drug price and kept capital chain stable. Under"two invoice system",drug circulation enterprises should actively adapt to the transformation of medical and pharmaceutical market,and reconstruct the chain of drug circulation. The integration of medical circulation network should be established between the relevant departments and various subjects. Drug circulation subjects should promote the check of ticket,account and goods,standardize the date of back account,implement reform stably.
引文
[1]何倩,曹丽君.我国药品流通体制的现状、问题及对策[J].中国医疗保险,2012,5(6):56-59.
[2]肖道安.医药企业“过票”行为的危害及对策[J].科技经济市场,2012,28(11):73-75.
[3]黄河,孙静,刘远立.“两票制”药品流通领域改革探讨[J].中国药房,2017,28(18):2456-2459.
[4]新华网.我国公立医疗机构药品采购推行“两票制”[EB/OL].(2017-01-09)[2017-09-02].http://news.xinhuanet.com/health/2017-01/09/c_1120274317.htm.
[5]陈钊.药品购销“两票制”政策的理论和实践[J].现代经济信息,2017(4):76.
[6]许方霄,高军.“两票制”的路途不会平坦[J].首都食品与医药,2016(15):26-27.
[7]国务院办公厅.关于印发《深化医药卫生体制改革2016年重点工作任务的通知》[EB/OL].(2016-04-26)[2017-09-02].http://www.gov.cn/zhengce/content/2016-04/26/content_5068131.htm.
[8]国务院办公厅.关于进一步改革完善药品生产流通使用政策的若干意见[EB/OL].(2017-02-09)[2017-09-02].http://www.gov.cn/zhengce/content/2017-02/09/content_5166743.htm.
[9]马文伟,郝志宏.两票制对医药流通企业的影响[J].现代经济信息,2017(13):339-340.
[10]孙茜.医改重头戏:“两票制”真的要来了[J].中国医院院长,2016(9):30-31.
[11]李姣,侯艳红.医改背景下药品流通企业发展路径分析[J].价格月刊,2015(6):91-94.
[12]姜天一.三明:“两票制”堵住加价漏洞[J].中国卫生,2016(5):19-20.
[13]覃拥.新政引发医药商业物流变革[J].物流技术与应用,2016,21(8):64-67.
[14]董维嘉.财政部调研:双成药业和国药星鲨产品价格混乱[EB/OL].(2014-12-19)[2017-09-02].http://gb.cri.cn/45731/2014/12/19/6851s4810151.htm.
[15]张馨月,雷寒.药品供应链管理的现状、问题及JIT模式[J].中国医院药学杂志,2013,33(2):152-154.
[16]刘志勇.两票制:怎样才能釜底抽薪[N].健康报,2016-04-28(005).
[17]王雪莹,雷晓盛.公立医院破除“以药养医”后的补偿机制思考[J].管理观察,2017(4):100-103.
[18]黄丽君,干荣富.对药品采购实施两票制的分析与思考[J].上海医药,2016,37(17):61-67.
[19]张帆,王帆,侯艳红.“两票制”下药品供应链的重塑和发展[J].卫生经济研究,2017(4):11-15.
[20]罗晶晶.治理药价虚高需要“晒”[N].中国会计报,2016-04-22(001).
[21]李格林.医药电商模式对我国医药供应链的优化作用分析[J].中国卫生信息管理杂志,2015,12(3):304-307、327.
[22]史丽丽.药品供应链现状分析[J].价值工程,2011,30(36):10-11.
[2]肖道安.医药企业“过票”行为的危害及对策[J].科技经济市场,2012,28(11):73-75.
[3]黄河,孙静,刘远立.“两票制”药品流通领域改革探讨[J].中国药房,2017,28(18):2456-2459.
[4]新华网.我国公立医疗机构药品采购推行“两票制”[EB/OL].(2017-01-09)[2017-09-02].http://news.xinhuanet.com/health/2017-01/09/c_1120274317.htm.
[5]陈钊.药品购销“两票制”政策的理论和实践[J].现代经济信息,2017(4):76.
[6]许方霄,高军.“两票制”的路途不会平坦[J].首都食品与医药,2016(15):26-27.
[7]国务院办公厅.关于印发《深化医药卫生体制改革2016年重点工作任务的通知》[EB/OL].(2016-04-26)[2017-09-02].http://www.gov.cn/zhengce/content/2016-04/26/content_5068131.htm.
[8]国务院办公厅.关于进一步改革完善药品生产流通使用政策的若干意见[EB/OL].(2017-02-09)[2017-09-02].http://www.gov.cn/zhengce/content/2017-02/09/content_5166743.htm.
[9]马文伟,郝志宏.两票制对医药流通企业的影响[J].现代经济信息,2017(13):339-340.
[10]孙茜.医改重头戏:“两票制”真的要来了[J].中国医院院长,2016(9):30-31.
[11]李姣,侯艳红.医改背景下药品流通企业发展路径分析[J].价格月刊,2015(6):91-94.
[12]姜天一.三明:“两票制”堵住加价漏洞[J].中国卫生,2016(5):19-20.
[13]覃拥.新政引发医药商业物流变革[J].物流技术与应用,2016,21(8):64-67.
[14]董维嘉.财政部调研:双成药业和国药星鲨产品价格混乱[EB/OL].(2014-12-19)[2017-09-02].http://gb.cri.cn/45731/2014/12/19/6851s4810151.htm.
[15]张馨月,雷寒.药品供应链管理的现状、问题及JIT模式[J].中国医院药学杂志,2013,33(2):152-154.
[16]刘志勇.两票制:怎样才能釜底抽薪[N].健康报,2016-04-28(005).
[17]王雪莹,雷晓盛.公立医院破除“以药养医”后的补偿机制思考[J].管理观察,2017(4):100-103.
[18]黄丽君,干荣富.对药品采购实施两票制的分析与思考[J].上海医药,2016,37(17):61-67.
[19]张帆,王帆,侯艳红.“两票制”下药品供应链的重塑和发展[J].卫生经济研究,2017(4):11-15.
[20]罗晶晶.治理药价虚高需要“晒”[N].中国会计报,2016-04-22(001).
[21]李格林.医药电商模式对我国医药供应链的优化作用分析[J].中国卫生信息管理杂志,2015,12(3):304-307、327.
[22]史丽丽.药品供应链现状分析[J].价值工程,2011,30(36):10-11.